文献速递头颈部肿瘤放疗

人乳头瘤病毒相关扁桃体癌接受单侧与双侧调强放疗的患者自报与医生报告结局:TROG 12.01子研究

Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy-A Substudy From TROG 12.01.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-08-10

该TROG 12.01子研究纳入74例侧方T1-2 N1-2b人乳头瘤病毒相关扁桃体癌患者(单侧放疗26例,双侧放疗48例),比较两组患者自报与医生报告结局。主要终点2年MDASI-RSS评分两组无差异(1.1 vs 1.3,差值0.1,95%CI -0.7~0.9,P=.75);双侧组治疗1周MDASI-SI及疲乏更差,2年口干更差。结论认为治疗侧别所致差异少于预期,需更长随访确定对晚期效应的影响。

要点

  • 2年MDASI-RSS评分单侧组1.1 vs 双侧组1.3,差值0.1(95%CI -0.7~0.9),P=.75,无差异。
  • 双侧组治疗1周MDASI-SI更差(4.7 vs 5.6),疲乏更差(6.6 vs 5.4)。
  • 双侧组2年口干更差(3.5 vs 2.0);FACT-HN、HADS、复工、PSS-HN及CTCAE两组相似。

核心结论

  • 在该有利风险队列中,治疗侧别对患者自报或医生报告结局造成的差异少于预期。
  • 治疗后2年,接受双侧放疗的患者报告口干显著更差。
  • 需要更长随访以确定治疗侧别对晚期效应的影响。

研究设计与样本

  • TROG 12.01子研究,纳入侧方T1-2 N1-2b人乳头瘤病毒相关扁桃体癌(AJCC7)患者。
  • 共74例可分析(单侧放疗26例,双侧放疗48例),中位随访3.7年(1.8-5.2年)。
  • 主要终点为2年患者自报放疗症状严重程度评分(MDASI-RSS),由9个MDASI头颈症状条目组成复合评分。

主要发现

  • 2年MDASI-RSS评分单侧组 vs 双侧组为1.1 vs 1.3,差值0.1(95%CI -0.7~0.9),P=.75。
  • MDASI-RSS、MDASI-SS及MDASI-SI在其他时间点均无差异,唯双侧组治疗1周MDASI-SI更差(4.7 vs 5.6)。
  • 双侧组治疗1周疲乏更差(6.6 vs 5.4),2年口干更差(3.5 vs 2.0)。
  • FACT-HN、HADS、复工、PSS-HN及CTCAE结果在随访期间两组相似。
  • 报告4例区域失败(单侧组3例,双侧组1例),包括单侧组1例孤立对侧区域失败。

局限性

  • 需要更长随访以确定治疗侧别对晚期效应的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this TROG 12.01 substudy was to report longitudinal variations in patient- (PRO) and clinician-reported outcomes based on receipt of unilateral (URT) or bilateral radiation therapy (BRT). METHODS AND MATERIALS: Patients with lateralized T1-2 N1-2b human papillomavirus-associated tonsillar carcinoma (AJCC7) enrolled on TROG 12.01 were eligible. The primary endpoint was patient-reported radiation symptom severity score (MDASI-RSS) at 2 years, a composite of 9 MDASI-Head and Neck (HN) symptom items. Secondary endpoints included patient-reported symptom burden and interference (MDASI-HN), quality of life (FACT-HN), emotional distress (HADS), return to work (RTW), clinician-reported performance status scale (PSS-HN), and late adverse events (CTCAE). Mean MDASI-RSS, symptom severity (MDASI-SS), symptom interference (MDASI-SI) and selected single items were compared 1 week, 3 months, and 2 years post-RT. RESULTS: Seventy-four patients were eligible for analysis (26 URT, 48 BRT). Median follow-up was 3.7 years (1.8-5.2 years). Sociodemographic, staging, and treatment variables were mostly balanced, with larger primaries observed in the BRT group. Four regional failures were reported (3 URT, 1 BRT), including one isolated contralateral regional failure in the URT cohort. Mean MDASI-RSS scores did not differ at 2 years (URT vs BRT, 1.1 vs 1.3; difference 0.1 [95% CI: -0.7 to 0.9], P = .75) or at any other time points for the MDASI-RSS, MDASI-SS, and MDASI-SI scores, except for worse MDASI-SI 1 week after treatment in the BRT group (4.7 vs 5.6). Fatigue (6.6 vs 5.4) at 1 week and dry mouth (3.5 vs 2.0) at 2 years were also worse in the BRT group. FACT-HN, HADS, RTW, PSS-HN, and CTCAE results were similar across the follow-up period. CONCLUSIONS: In this favorable-risk cohort, treatment laterality resulted in fewer differences than anticipated in patient-reported or clinician-reported outcomes. Two years after treatment patients treated with BRT reported significantly worse dry mouth. Longer follow-up is needed to determine the impact of treatment laterality on late effects.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McDowell L, Rischin D, King M, et al. Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy-A Substudy From TROG 12.01. Int J Radiat Oncol Biol Phys. 2022. PMID: 35961477. doi:10.1016/j.ijrobp.2022.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。